Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Alphabet joins the DJIA and gains over 4%🚀
Will the AI boom force Apple to use memory chips on the Pentagon’s “blacklist”?❓A U.S. senator responds🏛️
"Rammmagedon” ends up in court: Antitrust lawsuit and investments in Korea
Rocket Lab Acquires Iridium: The Birth of a New Space Infrastructure Leader?